Payment overview · 2025
General Payments
$2,860.63
100 reported records · 34 companies
Healthcare provider profile · identity verified
Gary L Pattee, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · LINCOLN, NE · NPI 1396794749
Verified facts
What the public records show
CMS Open Payments records show Gary L Pattee, M.D. received $2,860.63 in general payments during 2025 across 100 reported records.
Tanabe Pharma America, Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Radicava Ors.
Tanabe Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Radicava ORS as an associated drug or biological on 38 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Radicava Ors by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $734.56 | 25.7% | 10 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $299.62 | 10.5% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $138.09 | 4.8% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $111.50 | 3.9% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $101.30 | 3.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $98.52 | 3.4% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $93.44 | 3.3% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $91.08 | 3.2% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $88.39 | 3.1% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $84.88 | 3.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $83.40 | 2.9% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.24 | 2.6% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $71.57 | 2.5% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $65.42 | 2.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $65.02 | 2.3% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.58 | 2.2% | 3 | 2025 |
| Amicus Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.37 | 2.1% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $58.96 | 2.1% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $55.73 | 1.9% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$53.54 | 1.9% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $47.38 | 1.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.68 | 1.3% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $37.34 | 1.3% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $31.15 | 1.1% | 2 | 2025 |
| ITF Therapeutics LLC | Unresolved — no canonical attribution shown | $30.37 | 1.1% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.07 | 0.9% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.36 | 0.8% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $21.53 | 0.8% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $21.33 | 0.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.70 | 0.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.60 | 0.7% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.83 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.18 | 0.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.90 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,050.73 | 96 |
| Travel and Lodging | $642.00 | 2 |
| Consulting Fee | $150.00 | 1 |
| Education | $17.90 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $734.56 | 10 | 2025 |
Source payment records
|
|||||
| Radicava ORS Normalized: radicava ors |
Drug | Tanabe Pharma America, Inc. | $670.82 | 3 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $184.77 | 3 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $101.30 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $100.99 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.80 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $93.44 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $83.40 | 5 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $73.24 | 4 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $68.83 | 3 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $68.83 | 3 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $67.08 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $65.42 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $65.02 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $63.58 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $58.96 | 2 | 2025 |
Source payment records
|
|||||
| AGAMREE Normalized: agamree |
Drug | CATALYST PHARMACEUTICALS, INC. | $49.76 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $47.38 | 2 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $46.02 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $37.34 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $37.09 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $31.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $31.44 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $30.07 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $26.33 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $26.07 | 1 | 2025 |
Source payment records
|
|||||
| LINQ II Normalized: linq ii |
Device | Medtronic, Inc. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological | Octapharma USA, Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $21.33 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Radicava ORS radicava ors |
2025 | Radicava Ors | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Tanabe Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | Radicava ORS open payments reported associated product |
CMS Open Payments — General Payments 38 supporting records · 8 recipient NPIs · example record 1243917980 |
Radicava Ors · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Carbidopa-Levodopa | Carbidopa/Levodopa | 183 | 35 |
| Levetiracetam | Levetiracetam | 169 | 29 |
| Gabapentin | Gabapentin | 103 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 25 |
| Lamotrigine | Lamotrigine | 80 | suppressed |
| Levetiracetam Er | Levetiracetam | 80 | 12 |
| Memantine Hcl | Memantine Hcl | 77 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 74 | 16 |
| Donepezil Hcl | Donepezil Hcl | 64 | 14 |
| Prednisone | Prednisone | 58 | 12 |
| Radicava Ors | Edaravone | 53 | suppressed |
| Riluzole | Riluzole | 50 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 49 | suppressed |
| Carbamazepine Er | Carbamazepine | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 37 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 35 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 33 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Levocarnitine | Levocarnitine | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Austedo | Deutetrabenazine | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Keppra | Levetiracetam | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Relyvrio | Sod Phenylbutyrat/Taurursodiol | 16 | suppressed |
| Tegretol Xr | Carbamazepine | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 13 | suppressed |
| Depakote Er | Divalproex Sodium | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Horizant | Gabapentin Enacarbil | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 12 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 12 | suppressed |
| Chenodal | Chenodiol | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,860.63 · 100 records | Tanabe Pharma America, Inc. | ACTHAR, AGAMREE, AUSTEDO XR, Briviact, EPIDIOLEX, FIRDAPSE, Fintepla, HYQVIA, Hizentra, INBRIJA, KESIMPTA, KEVEYIS, KISUNLA, LINQ II, Leqembi, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QALSODY, QULIPTA, REXULTI, Radicava, Radicava ORS, Rystiggo, SPINRAZA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, VUMERITY, VYALEV, Xeomin, ZAVZPRET, ZEPOSIA, Zilbrysq | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Radicava Ors play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Tanabe Pharma America, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error